Novel approaches to plant drug discovery based on high throughput pharmacological screening and genetic manipulation

被引:28
|
作者
Littleton, J
Rogers, T
Falcone, D
机构
[1] Univ Kentucky, KTRDC, Lexington, KY 40546 USA
[2] Univ Massachusetts, Dept Biol Sci, Lowell, MA 01854 USA
关键词
drug discovery; plants; nicotinic acetylcholine receptors; radioligand binding; NICOTINIC ACETYLCHOLINE-RECEPTORS; ALPHA-BUNGAROTOXIN; ALZHEIMERS-DISEASE; BINDING-SITES; RAT-BRAIN; NEUROPROTECTION; (-)-NICOTINE;
D O I
10.1016/j.lfs.2005.09.013
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Plants are potentially important for novel therapeutic drug leads, but the slowness of conventional methods for investigation of plants limits enthusiasm in the pharmaceutical industry. To overcome some of the drawbacks, we have applied high throughput pharmacological screening (HTPS) to crude plant extracts. Using a "differential smart screen", (DSS) the spectrum of activity contained in a crude extract is measured at several closely related receptor subtypes. This spectrum is then compared to that of known compounds. A unique spectrum suggests that the extract merits further investigation. Evaluation of species and environmental libraries of whole plants has demonstrated the value of this approach for rapid prioritization of plants for investigation. In addition, genomic and genetic manipulation of plants and plant cell cultures can increase the value of DSS. For example, the whole genomic potential of a plant species for biodiversity can be accessed by using gain of function mutations to generate a "functional genomics library" of mutant clonal cultures, and the bioactivity of these cultures tested by DSS. Clones that overproduce activity differing from the wild-type plant can be identified in this way. This "Natural Products Genomics" (NPG) strategy is limited by the massive numbers of clonal cultures that are required to cover all possible gain-of-function mutations. The rapidity and efficiency of this process can be improved by using transgenic plants expressing appropriate mammalian proteins. These may be designed to make the plant cell resemble a human cell for a specific form of toxicity. Now, "unnatural selection" of resistant mutant clones can be used to provide a sub-population potentially enriched in useful compounds. Alternatively, transgenic plant cells can be used for "in situ screening" in which a mammalian receptor protein, linked to a reporter construct, such as green fluorescent protein, is expressed. Clonal cultures that produce ligands for this receptor can now be rapidly identified visually in an ultra-HTPS. Overall, our aim is to use pharmacological screening, together with functional genomic approaches, to make plant drug discovery competitive with combinatorial chemistry. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:467 / 475
页数:9
相关论文
共 50 条
  • [31] Ligand and structure-based virtual screening approaches in drug discovery: minireview
    da Rocha, Matheus Nunes
    de Sousa, Damiao Sampaio
    Mendes, Francisco Rogenio da Silva
    dos Santos, Helcio Silva
    Marinho, Gabrielle Silva
    Marinho, Marcia Machado
    Marinho, Emmanuel Silva
    MOLECULAR DIVERSITY, 2024, : 2799 - 2809
  • [33] Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets
    Vasaikar, Suhas
    Bhatia, Pooja
    Bhatia, Partap G.
    Yaiw, Koon Chu
    BIOMEDICINES, 2016, 4 (04)
  • [34] A solid-phase glycosyltransferase assay for high-throughput screening in drug discovery research
    Donovan, RS
    Datti, A
    Baek, MG
    Wu, QQ
    Sas, IJ
    Korczak, B
    Berger, EG
    Roy, R
    Dennis, JW
    GLYCOCONJUGATE JOURNAL, 1999, 16 (10) : 607 - 615
  • [35] A solid-phase glycosyltransferase assay for high-throughput screening in drug discovery research
    Rob S. Donovan
    Alessandro Datti
    Myung-Gi Baek
    Qingquan Wu
    Ian J. Sas
    Bozena Korczak
    Eric G. Berger
    René Roy
    James W. Dennis
    Glycoconjugate Journal, 1999, 16 : 607 - 615
  • [36] High-Throughput Screening of Biodiversity for Antibiotic Discovery
    Terekhov, S. S.
    Osterman, I. A.
    Smirnov, I. V.
    ACTA NATURAE, 2018, 10 (03): : 23 - 29
  • [37] High-Throughput Screening for the Discovery of Enzyme Inhibitors
    Lloyd, Matthew D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 10742 - 10772
  • [38] Innovative Approach of High-Throughput Screening in the Drug Discovery Quest for Chronic Bronchitis Treatment
    Naveed, Muhammad
    Javed, Khushbakht
    Aziz, Tariq
    Zafar, Ali
    Fatima, Mahnoor
    Rehman, Hafiz Muzzammel
    Khan, Ayaz Ali
    Alamri, Abdulhakeem S.
    Alsanie, Walaa F.
    Alhomrani, Majid
    JOURNAL OF COMPUTATIONAL BIOPHYSICS AND CHEMISTRY, 2025, 24 (02): : 173 - 187
  • [39] High-throughput Behavior-based Neuroactive Drug Discovery in Zebrafish
    Kokel, David
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S283 - S284
  • [40] Pooling in high-throughput drug screening
    Kainkaryam, Raghunandan M.
    Woolf, Peter J.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (03) : 339 - 350